BC Innovations | Apr 11, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on five genomic loci could help predict the risk of glioblastoma multiforme (GBM) and SNPs on eight genomic loci could help predict the risk of non-GBM glioma. Genome-wide association studies in 12,496...
BC Innovations | May 21, 2015
Distillery Techniques

Techniques: mRNA levels in tumor exosomes as markers of response to cancer treatment

Biomarkers TECHNOLOGY: Plasma Markers A microfluidics chip-based method for detecting mRNA in tumor exosomes could help monitor response to cancer therapies. The immuno-magnetic exosome RNA (iMER) platform measures exosomal levels of mRNA via on-chip enrichment...
BC Innovations | Nov 20, 2014
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Ischemia/reperfusion injury N-methylpurine-DNA glycosylase (MPG; APNG; AAG) Mouse studies suggest inhibiting DNA base excision repair initiated by AAG could help prevent ischemia/reperfusion injury. In...
BC Week In Review | Jan 20, 2014
Company News

Celgene, NantWorks deal

Celgene partnered with the NantBioscience subsidiary of Patrick Soon-Shiong's NantWorks to develop a pipeline of cancer drugs using the nanoparticle albumin-bound (nab) technology Celgene gained in its acquisition of Soon-Shiong's former company, Abraxis Bioscience Inc....
BC Innovations | Jan 26, 2012
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer N-Methylpurine-DNA glycosylase (MPG; APNG) A study in cells and in patient tissue suggests inhibiting the DNA repair enzyme APNG...
BC Week In Review | Jul 25, 2005
Company News

GenoSpectra, National Center for Scientific Research deal

Genospectra received an exclusive worldwide license to the center's MPG drug delivery technology. The parties also partnered to develop a panel of delivery reagents to transfer molecules into live cells. Genospectra has exclusive marketing rights...
BioCentury | Jun 24, 2002
Politics, Policy & Law

NIH plans cause a stir abroad

In March, the NIH made a little-noticed announcement of plans that will affect the right of ownership to inventions made under funding agreements (grants, cooperative agreements, contracts, subgrants, and subcontracts) with foreign entities. In Europe...
BioCentury | Jun 24, 2002
Politics, Policy & Law

Germany to increase biotech funding

The German research ministry BMBF last week announced it was planning to increase its biotech funding for 2003 by 6.5% from E660 million ($624 million) to E703 million ($665 million). Funding for research proposals in...
Items per page:
1 - 8 of 8